Title : Memantine ER/Donepezil: A Review in Alzheimer's Disease.

Pub. Date : 2015 Nov

PMID : 26519339






6 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Memantine ER/Donepezil: A Review in Alzheimer"s Disease. Memantine epiregulin Homo sapiens
2 A once-daily, fixed-dose combination of memantine extended-release (ER)/donepezil 28/10 mg (Namzaric ) is available in the USA for patients with moderate to severe Alzheimer"s disease (AD) on stable memantine and donepezil therapy. Memantine epiregulin Homo sapiens
3 In a 24-week, phase III trial in patients with moderate to severe AD, addition of memantine ER 28 mg once daily to stable cholinesterase inhibitor (ChEI) therapy was more effective than add-on placebo on measures of cognition, global clinical status, dementia behaviour and semantic processing ability, although between-group differences on a measure of daily function did not significantly differ. Memantine epiregulin Homo sapiens
4 In subgroup analyses in donepezil-treated patients, add-on memantine ER was more effective than add-on placebo on measures of cognition, dementia behaviour and semantic processing, although there were no significant between-group differences on measures of global clinical status and daily function. Memantine epiregulin Homo sapiens
5 Memantine ER plus ChEI combination therapy was generally well tolerated in the phase III trial, with diarrhoea, dizziness and influenza occurring at least twice as often with add-on memantine ER as add-on placebo in donepezil-treated patients. Memantine epiregulin Homo sapiens
6 Thus, memantine ER plus donepezil combination therapy is an effective and well tolerated treatment option for patients with moderate to severe AD. Memantine epiregulin Homo sapiens